Skip to main content
Clinical Trials/NCT04909983
NCT04909983TerminatedNot Applicable

A Single Center Explorative Study of the Treamtent ofDiabetes Patients With Contact Dermatitits Caused byInsulin Infusion Pump or Glucose Monitor

Copenhagen University Hospital at Herlev1 site in 1 country17 target enrollmentStarted: May 19, 2021Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Not Applicable
Status
Terminated
Sponsor
Enrollment
17
Locations
1
Primary Endpoint
Response rate of active treatment versus standard of care

Study Overview

Brief Summary

A feasibility study of treatment with a occlusive medical device or patch in pediatric patients with type 1 diabetes suffering from irritative contact dermatitis due to diabetes devices.

Study Design

Study Type
Interventional
Allocation
Non Randomized
Intervention Model
Crossover
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Ages
6 Years to 20 Years (Child, Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Signed informed consent, and for patients under the legal age consent by a legal guardian
  • •Clinically confirmed, active and evaluable irritant contact dermatitis (ICD)
  • •Age 6-20 at the time of signing the informed consent form (ICF)
  • •Ability to answer study questionnaires

Exclusion Criteria

  • •Any type of skin irritation other than ICD
  • •Use of occlusive therapy for the treatment of their ICD, or unwilling to refrain from this treatment for duration of study
  • •For any other reason considered unsuitable by the investigator
  • •Pregnant or of child-bearing potential unwilling to use acceptable effective contraception

Arms & Interventions

Intervention

Experimental

Medical Device, an occlusive patch for 3 days.

Intervention: DPLX-PT1 (Device)

Control

Active Comparator

Standard of Care

Intervention: Control arm (Other)

Outcomes

Primary Outcomes

Response rate of active treatment versus standard of care

Time Frame: 8 days after active treatment compared to 8 days after standard of care

Secondary Outcomes

  • Time to resolution of Irritative contact dermatitis(After 8 days)

Investigators

Sponsor
Copenhagen University Hospital at Herlev
Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Anna Korsgaard Berg

Principal Investigator MD

Copenhagen University Hospital at Herlev

Study Sites (1)

Loading locations...

Similar Trials